Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma - Wikidata - wikimedia - TriplyDB

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma

http://www.wikidata.org/entity/Q36726780

about

Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness.Economic impact of disease progression in follicular non-Hodgkin lymphoma.Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.Expressions of uroplakins in the mouse urinary bladder with cyclophosphamide-induced cystitis.Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review.Cost-effectiveness of rituximab in follicular lymphoma.Trends and issues in oncology costs.Are high drug prices for hematologic malignancies justified? A critical analysis.The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology.Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK.Preservation of uroplakins by 2-mercaptoethanesulfonate in cyclophosphamide-induced rat cystitis.SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.Urinary uroplakin expression in cyclophosphamide-induced rat cystitis model.Intravesical epinephrine preserves uroplakin II expression in urinary bladder from cyclophosphamide-induced rat cystitis.Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden

P2860

Q28535043-378716B8-5DFF-49D6-8D61-3FD073F8DDC1 Q35186372-E35E283C-F6A1-4C5D-B029-585563304036 Q35205349-43B9E44B-830D-4736-9C0A-326C59C0F7EB Q35536558-2DFA2D27-BB55-469E-A369-E03B8C8FB9A9 Q36210598-F02D8DF4-84A0-498B-A33E-AEAD738A9381 Q37284704-B6D95BC6-3490-4EEA-B0DC-A60486DAAC75 Q38011852-25017034-BAAB-46D8-8817-8FE89C549651 Q38058840-0454E51C-AEAE-4C97-8481-D325B1B6878E Q38170426-68899D92-7230-4316-957C-B83EC99AFFF6 Q38535347-7909E71E-1BBC-4D82-A510-5A283A341957 Q38610648-D0B6477B-0124-4112-8F31-911A03824E2A Q42649795-0906F0F6-6595-4331-A2CD-F7FA729745B6 Q43148758-3FEB254B-E6DF-45E3-98E1-159FBB03741F Q44908024-4F546627-0D58-49BF-A12E-95CDB2A2A673 Q50892830-86A14DCB-8E46-4BD3-93F6-F7FC881D1046 Q50977201-B6811E90-B9FB-491A-9FB6-141B4C2FAA38 Q51336777-F139AC96-3055-49BB-9830-B02C8677FA50 Q54261595-AA68BAD5-CCBC-4E9A-99F5-C5E4AD96DEED Q58803120-2A536DA0-D79B-4748-BE4D-CEB0202D4321

P2860

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma

http://www.wikidata.org/entity/Q36726780

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Economic evaluation of rituxim ...... r advanced follicular lymphoma

@ast

Economic evaluation of rituxim ...... r advanced follicular lymphoma

@en

type

label

Economic evaluation of rituxim ...... r advanced follicular lymphoma

@ast

Economic evaluation of rituxim ...... r advanced follicular lymphoma

@en

prefLabel

Economic evaluation of rituxim ...... r advanced follicular lymphoma

@ast

Economic evaluation of rituxim ...... r advanced follicular lymphoma

@en

P1433

Q36726780-77381677-6F00-4FB5-A8B0-B162E86E0CA9

P1476

Q36726780-EA2D0728-34E6-4621-8401-B018D53D6E30

P2093

Q36726780-0A6EAC4D-230F-41E7-BC4A-CF3A514567D4

Q36726780-651A22D9-17FA-4346-BC3B-D93F547B4250

Q36726780-6690CC7B-860D-4DDC-88AA-23737DB2C61D

Q36726780-C242468F-F9F5-47F0-8C82-4CCDC057D7E8

P2860

Q36726780-0701A3F7-51A8-431B-9970-930CE552AC20

Q36726780-09AD6553-82AA-4939-AF37-2461435F7903

Q36726780-0FA05B0A-B5FA-424E-84B5-3800165568B1

Q36726780-1823C84B-A8D0-413A-99CF-5AB5909CBB44

Q36726780-1C319E3D-F368-444C-BE8C-12951F1A1FFB

Q36726780-2D7C5C6A-FFBB-4A04-826F-301759FDFF99

Q36726780-4434299F-D519-4ED9-A72A-622E691B8CC6

Q36726780-5359D8FD-51EC-48FA-B106-31E4A95A4E58

Q36726780-540CF224-672E-41E2-84C3-EDA0DA0A27E0

Q36726780-879B630A-4386-4E50-8D7A-227CB99B2CE8

P304

Q36726780-A9CBD6EA-102C-4076-ADBC-B39C5BCDB1A1

P31

Q36726780-9E004A28-9659-453B-8356-F15156B9A9BB

P356

Q36726780-BD886604-D5E8-488B-971C-E53F38F740F6

P433

Q36726780-B9BD8A45-1D06-457C-81EA-8E9D88C911A0

P478

Q36726780-7ECF3391-3232-4046-AFAB-10672FFD83CC

P577

Q36726780-EF3C403A-D0AC-47D1-B71A-39BA4493B29D

P5875

Q36726780-6EE53799-24A4-44A1-BD57-B4ABA008C1A7

P698

Q36726780-77C70721-D994-4244-8F29-B04DF9BD029C

P932

Q36726780-5A573FED-0875-4B5D-B9B4-1F1FBB019131

P356

10428190701769665

P1433

Leukemia & Lymphoma

P1476

Economic evaluation of rituxim ...... r advanced follicular lymphoma

@en

P2093

Carolina Reyes

http://www.w3.org/2001/XMLSchema#string

Deborah Lubeck

http://www.w3.org/2001/XMLSchema#string

John Hornberger

http://www.w3.org/2001/XMLSchema#string

Nancy Valente

http://www.w3.org/2001/XMLSchema#string

P2860

Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey

Grading quality of evidence and strength of recommendations

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

Are pharmaceuticals cost-effective? A review of the evidence.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

Advances in follicular lymphoma.

The clinical course of follicular lymphoma.

Incorporating quality of evidence into decision analytic modeling.

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.

Natural history of and therapy for the indolent non-Hodgkin's lymphomas.

P304

227-236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190701769665

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5619875

http://www.w3.org/2001/XMLSchema#string

P698

18231908

http://www.w3.org/2001/XMLSchema#string

P932

2430747

http://www.w3.org/2001/XMLSchema#string